000			02089 a2200601 4500
005			20250514162247.0
264		0	_c20040209
008			200402s 0 0 eng d
022			_a0887-4476
024	7		_a10.1002/syn.10293 _2doi
040			_aNLM _beng _cNLM
100	1		_aForsback, Sarita
245	0	0	_aUptake of 6-[18F]fluoro-L-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease. _h[electronic resource]
260			_bSynapse (New York, N.Y.) _cFeb 2004
300			_a119-27 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAmphetamine _xpharmacology
650	0	4	_aAnimals
650	0	4	_aApomorphine _xpharmacology
650	0	4	_aAutoradiography
650	0	4	_aBehavior, Animal _xdrug effects
650	0	4	_aBrain _xanatomy & histology
650	0	4	_aBrain Mapping
650	0	4	_aCentral Nervous System Stimulants _xpharmacology
650	0	4	_aDihydroxyphenylalanine _xanalogs & derivatives
650	0	4	_aDisease Models, Animal
650	0	4	_aDopamine Agonists _xtoxicity
650	0	4	_aFunctional Laterality
650	0	4	_aImmunohistochemistry
650	0	4	_aLevodopa _xpharmacology
650	0	4	_aMale
650	0	4	_aOxidopamine _xtoxicity
650	0	4	_aParkinson Disease _xmetabolism
650	0	4	_aPropionates _xpharmacokinetics
650	0	4	_aRadioligand Assay
650	0	4	_aRats
650	0	4	_aRats, Sprague-Dawley
650	0	4	_aStereotyped Behavior _xdrug effects
650	0	4	_aSubstantia Nigra _xmetabolism
650	0	4	_aSympatholytics _xtoxicity
650	0	4	_aTyrosine 3-Monooxygenase _xmetabolism
700	1		_aNiemi, Riitta
700	1		_aMarjamäki, Päivi
700	1		_aEskola, Olli
700	1		_aBergman, Jörgen
700	1		_aGrönroos, Tove
700	1		_aHaaparanta, Merja
700	1		_aHaapalinna, Antti
700	1		_aRinne, Juha
700	1		_aSolin, Olof
773	0		_tSynapse (New York, N.Y.) _gvol. 51 _gno. 2 _gp. 119-27
856	4	0	_uhttps://doi.org/10.1002/syn.10293 _zAvailable from publisher's website
999			_c14355548 _d14355548